Register
for UpdatesSend to a
Friend Text Size
A A A Print
Page

Important Safety Information Full Prescribing Information Patient Package Insert Instructions For Use

Watch and Learn

Watch and Learn

Watch and Learn

Tyvaso Treatment Tracker

Keeping track of your 4 times daily dosing is important to your pulmonary arterial hypertension (PAH) treatment success. In your first Tyvaso^® shipment from your Specialty Pharmacy Service provider, you’ll receive the Tyvaso Treatment Tracker, which is designed to help you track the number of breaths you take during each of your treatment sessions.

The treatment tracker is a monthly, pocket-size, personal diary that allows you to record treatment sessions. The diary consists of daily calendars organized by week. Each day, you’ll check 1 circle for every breath of Tyvaso taken during your individual treatment sessions. For example, if your doctor prescribes 9 breaths (3 cycles) of Tyvaso per treatment session, you’ll make sure to record your breaths after each cycle (3 breaths) and check 9 circles (for 9 breaths) 4 times each day.

Remember: 3 breaths equals 1 cycle in your treatment tracker.

Indication

Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase-5 inhibitor). The effects decrease over 4 hours; treatment timing can be adjusted for planned activities.

Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

Important Safety Information for Tyvaso

• Tyvaso is breathed in (inhalable) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System
• The effects of Tyvaso are unknown in patients with lung disease (such as asthma or chronic obstructive pulmonary disease) and in patients under 18 years of age
• If you have low blood pressure, Tyvaso may cause symptomatic hypotension (low blood pressure)
• Because Tyvaso reduces the ability of your blood to clot (coagulate), it may increase your risk for bleeding if you are taking blood thinners (anticoagulants), such as warfarin or heparin
• The use of Tyvaso with diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart disease), or other vasodilators (medications that lower blood pressure) may increase your risk for hypotension (low blood pressure)

Other medical conditions and medicines may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking, including:

• If you are taking gemfibrozil (for high cholesterol) or rifampin (for infection), your Tyvaso dosage may need adjustment
• If you have liver or kidney problems, your ability to tolerate Tyvaso may be affected
• If you are pregnant, breast-feeding, or planning to become pregnant, talk with your healthcare provider about whether you should take Tyvaso

The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your doctor about any side effects that bother you or do not go away. Your doctor may be able to help you manage the side effects.

For more information about Tyvaso, please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use Manual. Questions? Call the Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Tyvaso FAQs|Important Safety Information|Full Prescribing Information|Patient Package Insert|Instructions for Use Manual

Site Map|Contact Us|Privacy Policy|Terms of Use|About United Therapeutics

©2012 United Therapeutics Corporation. All rights reserved. V1
Tyvaso is a registered trademark of United Therapeutics Corporation. All other trademarks and registered trademarks are the property of their respective owners.
This site is intended for use by U.S. residents only.